A Phase II, Non-comparative, Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen

Trial Profile

A Phase II, Non-comparative, Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ATLANTIC
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Mar 2018 A protocol amendment (amendment 2) was incorporated to add a third cohort of patients with EGFR-/ALK- NSCLC, whose tumours had at least 90% of cells expressing PD-L1.
    • 12 Mar 2018 A protocol amendment (amendment 1) was implemented to include only patients with at least 25% of tumour cells with membranous staining, at any intensity, for PD-L1 expression per central assessment of recent or archival samples.
    • 12 Mar 2018 Results (n=444) assessing effects of Durvalumab in patients with locally advanced or metastatic non small cell lung cancer in terms of efficacy, safety and tolerability, were published in the Lancet Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top